Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV-MG01 in Myasthenia Gravis
NCT02609022Phase 2Completed
- Sponsor
- CuraVac
- Start
- Mar 2016
- Primary completion
- Sep 2018
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CV-MG01 in myasthenia gravis (MG), sponsored by CuraVac. Started Mar 2016; status: completed.
02
Drugs
CV-MG01
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT02609022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609022.